Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Drug Makers in Japan Upping Coronavirus Measures; Takeda Switches to Online Interviews for New R&D Hires
Drug makers in Japan are beefing up their measures against the novel coronavirus as the country scrambles to contain the further spread of the virus, with Astellas Pharma expanding its eligibility criteria for telecommuting to include sales reps. Astellas said…
To read the full story
Related Article
- Takeda to Maintain Partial Voluntary Ban on Sales Reps Activities in Japan amid Coronavirus Woes
May 8, 2020
- Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
- Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
- Sawai Refrains from Sales Reps' Doctor Visits Through March 13
March 4, 2020
- Pfizer Sales Reps Told to Avoid Doctor Visits, Stay at Home amid Coronavirus Woes
March 2, 2020
- Japan Drug Makers Fearing Manufacturing Crisis as Coronavirus Spreads
February 27, 2020
- Astellas, MSD Follow Suit to Boost Measures to Protect Employees from Coronavirus Infection
February 21, 2020
- Drug Makers in Japan Urging Staffers to Work at Home, Shun Rush-Hour Commuting amid Coronavirus Fears
February 19, 2020
BUSINESS
- Espha to Reinvest AG Profits into New Biz after Reform; Xarelto AG Logs 19 Billion Yen
May 15, 2026
- Meiji Opposes French Fund’s Push to Review Pharma Spin-Off
May 15, 2026
- FRONTEO Opens AI Drug Discovery Lab, Pivots to Out-Licensing Model
May 15, 2026
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…